<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873703</url>
  </required_header>
  <id_info>
    <org_study_id>MEI-003</org_study_id>
    <nct_id>NCT01873703</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled study is to determine the
      safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and
      FDA approved treatment for Myelodysplastic Syndrome (MDS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the relative efficacy, measured by complete remission rate of treatment wiht pracinostat plus azacitidine versus placebo plus azacitidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the overall response rate [ORR = CR + complete remission + partial response (PR)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the overall hematologic improvement (HI) response rate by review of hematologic lab values each cycle including bone marrow blast counts, platelets and erythrocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Estimate the progression-free survival (PFS) duration of pracinostat plus azacitidine and the relative benefit of that combination versus placebo plus azacitidine as assessed by the PFS hazard ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of leukemic transformation</measure>
    <time_frame>6 - 24 months</time_frame>
    <description>Estimate the rate of leukemic transformation at landmark time points (6 months, 12 months, 18 months, and 24 months) using clinical review of hematologic lab counts each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6-24 months</time_frame>
    <description>Estimate the overall survival (OS) duration of pracinostat plus azacitidine and the relative benefit of that combination versus placebo plus azacitidine as assessed by the OS hazard ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE profile</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the adverse event (AE) profile of pracinostat and placebo when combined with azacitidine by clinical review of safety events by grade, relationship and event outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>pracinostat plus azacitadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Azacitadine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pracinostat</intervention_name>
    <description>Histone deacetylase inhibitor (HDACi)</description>
    <arm_group_label>pracinostat plus azacitadine</arm_group_label>
    <other_name>SB939</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo with Azacitadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable</description>
    <arm_group_label>pracinostat plus azacitadine</arm_group_label>
    <arm_group_label>Placebo with Azacitadine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary written informed consent

          -  Histologically or cytologically documented diagnosis of MDS (any
             French-American-British [FAB] classification subtype; that is classified as
             intermediate 2 (1.5 to 2.0 points) or high risk (≥2.5 points) according to the
             International Prognostic Scoring System risk category, with &gt;5% and &lt;30% blasts, and a
             peripheral blast count of &lt;20,000

          -  Bone marrow aspirate smears and bone marrow biopsies within 28 days of first study
             treatment

          -  There must be a clinical indication for treatment with azacitidine.

          -  Previously untreated with hypomethylating agents (prior therapy with transfusions,
             hematopoietic growth factors, or immunosuppressive therapy is allowed)

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2

          -  Adequate organ function as evidenced by:

               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x the
                  upper limit of normal (ULN) (≤5 x ULN for patients with hepatic metastases

               2. Total bilirubin ≤1.5 x ULN or total bilirubin of 2, whichever is higher

               3. Serum creatinine &lt;2 mg/dL, or creatinine clearance ≤1.5 x ULN

               4. QTcF interval ≤470 msec

          -  Female or male patients ≥18 years-of-age

          -  Male patients who are surgically sterile or willing to use adequate contraceptive
             measures or abstain from heterosexual intercourse during the entire study treatment
             period

          -  Female patients who are surgically sterile or post menopausal or female patients who
             are not of child-bearing potential and female patients of child-bearing potential who
             agree to use adequate contraceptive measures or abstain from intercourse during the
             study treatment period, who are not breastfeeding, and who have had a negative serum
             pregnancy test ≤7 days prior to first study treatment.

          -  Willingness and ability to comply with the trial and follow-up procedures

        Exclusion Criteria:

          -  Received any of the following within the specified time frame prior to administration
             of study medication:

               1. Any investigational agent within 14 days or 5 half-lives prior to first study
                  treatment, whichever is longer

               2. Previous therapy for malignancy within 21 days prior to first study treatment,
                  including any chemotherapy, immunotherapy, biological or hormonal therapy (6
                  weeks for nitrosoureas or mitomycin C)

               3. Hydroxyurea within 48 hours prior to first study treatment

               4. Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating
                  factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or
                  thrombopoietin receptor agonists at least 7 days (14 days for Aranesp) prior to
                  study enrollment

               5. Major surgery within 4 weeks prior to first study treatment

          -  Patients that have not recovered from side effects of previous therapy

          -  Cardiopulmonary function exclusion:

               1. Current unstable arrhythmia requiring treatment

               2. History of symptomatic congestive heart failure (New York Heart Association
                  Classes III or IV)

               3. History of myocardial infarction within 6 months of enrollment

               4. Current unstable angina

          -  Concomitant treatment with histone deacetylase (HDAC) inhibitors or drugs with
             significant action as HDAC inhibitors, such as valproic acid, is not permitted

          -  Clinical evidence of central nervous system involvement

          -  Patients with gastrointestinal (GI) tract disease, causing the inability to take oral
             medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical
             procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's
             disease, ulcerative colitis).

          -  Active infection with HIV or chronic hepatitis B or C

          -  Life-threatening illness unrelated to cancer, or any serious medical or psychiatric
             illness that could, in the investigator's opinion, potentially interfere with
             participation in this study

          -  Presence of a malignant disease within the last 12 months, with the exception of
             adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or
             non-melanomatous skin cancer

          -  Inability (including psychological, familial, sociological, or geographical
             conditions) to comply with trial and/or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist and Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Ctr</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center, Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://MEIPharma.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>High risk myelodysplastic syndrome</keyword>
  <keyword>Intermediate-2 Myelodysplastic syndrome</keyword>
  <keyword>Untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

